All articles tagged: Acute respiratory distress syndrome (J80)

Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter published online July 3 in JAMA Network Open.Matthew M. Davis, M.D., from Nemours Children's Health in Wilmington, Delaware, and Lakshmi K. Halasyamani, M.D., from Endeavor Health in Eva

The risk for prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies across immunosuppressive conditions, according to a study published in the Jan. 24 issue of Science Translational Medicine.Yijia Li, M.D., from Harvard Medical School in Boston, and colleagues performed a detailed viro-immunologic analysis of a

In children and adolescents, BNT162b2 was effective for COVID-19-related outcomes during the delta and omicron periods, according to a study published online Jan. 9 in the Annals of Internal Medicine.Qiong Wu, Ph.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined the effectiveness

In children and adolescents, BNT162b2 was effective for COVID-19-related outcomes during the delta and omicron periods, according to a study published online Jan. 9 in the Annals of Internal Medicine.Qiong Wu, Ph.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined the effectiveness

Treatment with nirmatrelvir during acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not associated with a reduced risk for subsequent development of long COVID, according to a study published online Jan. 4 in the Journal of Medical Virology.Matthew S. Durstenfeld, M.D., from the University of California in

For patients with severe acute respiratory distress syndrome (ARDS) undergoing venovenous extracorporeal membrane oxygenation (VV-ECMO), prone positioning does not decrease the time to successful weaning compared with supine positioning, according to a study published in the Dec. 1 issue of the Journal of the American Medical Association.<

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound occurs at a similar rate for those receiving and not receiving oral antiviral treatment and for those receiving nirmatrelvir/ritonavir or placebo, according to research published in the Dec. 22 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality We

For patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs (DMARDs), receiving a fourth COVID-19 mRNA vaccine reduces the risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published online Nov. 15 in The Lancet Rheumatology.Jennifer S. Hanberg

The prevalence of olfactory dysfunction (OD) and gustatory dysfunction (GD) declines in the three years after COVID-19 infection, according to a research letter published online Nov. 9 in JAMA Otolaryngology-Head &amp; Neck Surgery.Paolo Boscolo-Rizzo, M.D., from the University of Trieste in Italy, and colleagues estimated the three-

Preexisting asthma or rhinitis may increase the risk for long COVID (LC), according to a review published online Nov. 8 in&nbsp;Clinical &amp; Experimental Allergy.Doreen Wolff, from the University of Magdeburg in Germany, and colleagues conducted a systematic literature review to examine the epidemiological evidence on allergic dise

The number of zoonotic spillover events and reported deaths increased by 4.98 and 8.7 percent, respectively, annually, according to a study published online Nov. 2 in BMJ Global Health.Amanda Jean Meadows, Ph.D., from Ginkgo Bioworks in Emeryville, California, and colleagues used an extensive epidemiological database to analyze a specifi

For trauma patients receiving mechanical ventilation at risk of poor outcomes, the addition of sigh breaths does not significantly increase ventilator-free days, according to a study published online Oct. 25 in the Journal of the American Medical Association to coincide with the annual congress of the European Society of Intensive Care Medic

Outpatient treatment of COVID-19 with nirmatrelvir-ritonavir (Paxlovid) reduces the risk for combined thromboembolic events, but does not affect the risk for other post-COVID-19 conditions (PCCs), according to a study published online Oct. 31 in the Annals of Internal Medicine.George N. Ioannou, B.M.B.Ch., from the University of Washin

For patients with COVID-19-induced acute respiratory distress syndrome (ARDS), administration of plasma from convalescent donors with a neutralizing antibody titer of at least 1:160 within five days after initiation of invasive mechanical ventilation reduces mortality at 28 days, according to a study published online Oct. 26 in the New England Jour